Where you can get Mounjaro in the UK

What the official guidance says about prescribing tirzepatide

NICE published its recommendation for tirzepatide (Mounjaro) in December 2024 (Technology Appraisal TA1026) and NHS England began phased rollout through specialist and primary care services shortly after. The appraisal drew on trial data from the SURMOUNT programme, in which thousands of adults taking tirzepatide saw average body-weight reductions of around 20–21% at the highest dose over 72 weeks. Those numbers gave NICE confidence to recommend it, but with defined eligibility thresholds rather than open access.

What that means practically: the fact that tirzepatide works well in trials does not automatically mean anyone who wants it can get it on the NHS. The guidance sets specific BMI and comorbidity requirements, which NHS England has built into a phased rollout. If you fall outside those thresholds (or simply do not want to wait) a private prescription is the alternative. A full overview of tirzepatide as a medicine covers the mechanism and licensed indications in more depth.

Getting Mounjaro on the NHS: the honest picture right now

NHS access to tirzepatide follows a staged plan. From June 2025, patients with a BMI of 40 or above and four or more qualifying conditions (which include type 2 diabetes, high blood pressure, dyslipidaemia, obstructive sleep apnoea and cardiovascular disease) became eligible. A second cohort, covering BMI 35–39.9 with four or more of those same conditions, opened in June 2026. Further cohorts are expected from around March 2027.

Lower BMI thresholds apply for some ethnic backgrounds under UK guidance, the NICE appraisal specifies a 2.5 kg/m² reduction for South Asian, Chinese, other Asian, Middle Eastern, Black African and African-Caribbean backgrounds. Even if you meet the numbers, every NHS patient must take part in diet and activity support alongside treatment, and participation varies by GP practice and integrated care board. Meeting the criteria is necessary; it is not, on its own, sufficient to guarantee a prescription this week. That gap between eligibility on paper and access in practice is a question our prescribers hear most weeks.

NHS England's guidance on weight-management injections sets out the full eligibility framework and what wraparound care looks like.

Where can you get tirzepatide privately, and what makes a source legitimate?

If you do not meet NHS thresholds yet, or do not want to wait, a private prescription from a GPhC-registered pharmacy is the legal route. The licensed eligibility criteria for private supply reflect the medicine's licence: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as prediabetes, hypertension or obstructive sleep apnoea. A prescriber still needs to assess you, that assessment cannot be skipped.

The MHRA has issued repeated warnings about fake tirzepatide pens circulating online. Some have contained the wrong substance entirely and caused hospitalisations. The reliable check is the GPhC pharmacy register: any legitimate online pharmacy dispensing prescription medicines in the UK must appear there. If a seller offers these medicines without requiring a proper consultation, that is a serious red flag, not a convenience.

At nume, consultations are reviewed the same day by a GPhC-registered Independent Prescriber, a real clinician reads your answers, not automated software. If you are approved, treatment is dispatched the same day for free next-working-day delivery. For a broader look at what to look for when choosing where to get Mounjaro, that page covers the safety checks worth running.

Injection sites, storage and a note on cost

Whichever route you use, a few practical facts hold. Mounjaro is a once-weekly subcutaneous injection given at the abdomen, thigh or upper arm, you rotate the site each week. The pen is pre-filled; a guide to Mounjaro injection sites goes into the detail if you want it. Pens are stored in the fridge at 2–8°C; the exact window for room-temperature use is in the Patient Information Leaflet, and that is always the reference for storage specifics.

On cost: private prices for tirzepatide have risen since Eli Lilly adjusted its UK list price in September 2025. The background to that price change is useful context before you compare providers. Typical private prices now range roughly £149–£375 per month by dose and provider, and any legitimate price includes clinical assessment, a prescription and dispensing. If a price looks far below that range, the question is what has been left out, clinically or logistically.

The Mounjaro overview page covers the full picture on results, side effects and how the medicine works. When you are ready to check your eligibility with a prescriber, starting a free consultation is the straightforward next step.